Business model
100% outsourcing:
- Mymetics has research contracts with highly specialised teams, drawing on experience and expertise recognised worldwide
- A major advantage of outsourcing is that it considerably reduces fixed costs and investments in equipment and material
- This strategy ensures maximum flexibility to orientate research in a field that is highly competitive and constantly evolving.
Innovative vaccine
Design:
- Removes distractive regions of the pathogen proteins
- Optimized for focusing the immune responses on relevant pathogen parts
- Targets the pathogen entry site(s)
- Targets the pathogen replication site(s)
Safety and tolerance:
- Our vaccines are based on the Virosome® technology (licensed from Pevion Biotech)::
− Constituted of lipidic vesicles derived from the influenza membrane
− Approved for human use in 43 countries
− Non replicative carrier
− Possesses intrinsic adjuvant properties
− Allows vaccination with multiple virosome-based vaccines
- Various administration routes are possible
- Low risk of triggering autoimmune side effects due to minimal human protein homologies in the vaccine components |
